Interesting that they list the US for other indications, but not respiratory:
Respiratory Disease
Paradigm Biopharmaceuticals Ltd has acquired patents over the use of PPS as a new treatment for respiratory diseases including Allergic Rhinitis (AR), Allergic Asthma (AA) and Chronic Obstructive Pulmonary Disease (COPS). Paradigm has registered patents in major markets including Australia, Canada, Europe, New Zealand, and The People’s Republic of China.
W
PAR and Coke, page-15
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 2777 | 1 |
View Market Depth
| Last trade - 09.28am 31/05/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
Day chart unavailable